MIA Polyclonal Antibody, Biotin, PeproTech®, Invitrogen™

Rabbit Polyclonal Antibody

Catalog Number	Mfr. No.	Quantity
50-271-8577	Invitrogen™ 500P243BT500UG	500 μg

Description

AA Sequence of recombinant protein: MGPMPKLADR KLCADQECSH PISMAVALQD YMAPDCRFLT IHRGQVVYVF SKLKGRGRLF WGGSVQGDYY GDLAARLGYF PSSIVREDQT LKPGKVDVKT DKWDFYCQ. Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human MIA. Anti-Human MIA-specific antibody was purified by affinity chromatography and then biotinylated. Sandwich ELISA: To detect hMIA by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.25-1.0 μg/mL of this antibody is required. This biotinylated polyclonal antibody, in conjunction with PeproTech Polyclonal Anti-Human MIA (500-P243) as a capture antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant hMIA. Western Blot: To detect hMIA by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant hMIA is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions. 500-P243BT-1MG will be provided as 2 x 500 μg

Tumorigenesis is a process that is mediated by a network of membrane, cytosolic and nuclear associated factors, which regulate proliferation and cell-matrix interaction through signaling cascades. The phenotype of malignant melanomas in vivo depends on the global expression of stimulatory or inhibitory factors generated in both the tumors cells and their environment. One example, Melanoma inhibitory activity (cartilage-derived retinoic acid-sensitive protein (CD-RAP), MIA) is a Src homology 3 (SH3)-like domain containing protein that is secreted from chondrocytes and malignant melanoma cells. MIA is translated as a 131-amino acid pro-form and processed into a mature 107-amino acid protein after cleavage of a secretion signal. MIA is expressed during chondrogenesis and in mature chondrocytes, suggesting that MIA is necessary for normal cartilage cell phenotype. MIA mRNA is present in carcinomas of the colon, ovary, kidney, and head/neck, and may represent a marker to monitor melanomic activity.

Specifications

• Antigen: MIA
• Applications: ELISA, Western Blot
• Conjugate: Biotin
• Host Species: Rabbit
• Target Species: Human
• Gene Accession No.: Q16674
• Gene ID (Entrez): 8190
• Immunogen: E.coli-derived Recombinant Human MIA.
• Purification Method: Antigen affinity chromatography
• Gene: MIA

• Concentration: 0.1-1.0 mg/mL
• Classification: Polyclonal
• Form: Lyophilized
• Regulatory Status: RUO
• Formulation: PBS with no preservative
• Gene Alias: cartilage derived retinoic acid sensitive protein; cartilage-derived retinoic acid-sensitive protein; Cdrap; CD-RAP; melanoma inhibitory activity; melanoma inhibitory activity 1; melanoma inhibitory activity protein; melanoma inhibitory activity/condrocyte-derived retinoic acid sensitive protein homolog (MIA/CD-RAP); melanoma-derived growth regulatory protein; melanoma-inhibitory-activity; MIA; Mia1
• Gene Symbols: MIA
• Primary or Secondary: Primary
• Content And Storage: -20°C